Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Akt1 deletion prevents lung tumorigenesis by mutant K-ras

Oncogene volume 30, pages 1812–1821 (2011)Cite this article

Subjects

Abstract

K-ras mutations are associated with smoking-induced lung cancer and poor clinical outcomes. In mice, K-ras mutations are sufficient to induce lung tumors, which require phosphoinoside-3-kinase (PI3K) and further downstream, mammalian target of rapamycin (mTOR) activation. However, the roles of individual Akt isoforms that link PI3K and mTOR are unknown. Here, we show that deletion of Akt1 but not Akt2 or Akt3 prevents lung tumorigenesis in a tobacco carcinogen-induced model and a genetic model. Akt1 deletion prevented tumor initiation as well as tumor progression, coincident with decreased Akt signaling in tumor tissues. In contrast, deletion of Akt3 increased tumor multiplicity in the carcinogen model and increased tumor size in the genetic model. Fibroblasts lacking Akt1 are resistant to transformation by mutant K-ras and stimulation by epidermal growth factor. Human lung cancer cells with mutant K-ras and diminished Akt1 levels fail to grow in vivo. These data suggest that Akt1 is the primary Akt isoform activated by mutant K-ras in lung tumors, and that Akt3 may oppose Akt1 in lung tumorigenesis and lung tumor progression. Given that Akt inhibitors in clinical development as cancer therapeutics are not isoform selective, these studies support specific targeting of Akt1 to mitigate the effects of mutant K-ras in lung cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA . (2010). AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 29: 150–155.

    Article  CAS  PubMed  Google Scholar 

  • Belinsky SA, Devereux TR, Maronpot RR, Stoner GD, Anderson MW . (1989). Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res 49: 5305–5311.

    CAS  PubMed  Google Scholar 

  • Bulavin D, Kovalsky O, Hollander M, Fornace AJ . (2003). Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell Biol 23: 3859–3871.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Buzzi F, Xu L, Zuellig RA, Boller SB, Spinas GA, Hynx D et al. (2010). Differential effects of protein kinase B/Akt isoforms on glucose homeostasis and islet mass. Mol Cell Biol 30: 601–612.

    Article  CAS  PubMed  Google Scholar 

  • Carpten J, Faber A, Horn C, Donoho G, Briggs S, Robbins C et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439–444.

    Article  CAS  PubMed  Google Scholar 

  • Chen M, Xu P, Peng X, Chen W, Guzman G, Yang X et al. (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/− mice. Genes Dev 20: 1569–1574.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cho H, Mu J, Kim J, Thorvaldsen J, Chu Q, Crenshaw Er et al. (2001a). Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292: 1728–1731.

    Article  CAS  PubMed  Google Scholar 

  • Cho H, Thorvaldsen J, Chu Q, Feng F, Birnbaum M . (2001b). Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276: 38349–38352.

    Article  CAS  PubMed  Google Scholar 

  • Cicenas J . (2008). The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 23: 1–9.

    Article  CAS  PubMed  Google Scholar 

  • Cully M, Downward J . (2008). SnapShot: Ras signaling. Cell 133: 1292–1292 e1291.

    Article  CAS  PubMed  Google Scholar 

  • Dannemann N, Hart JR, Ueno L, Vogt PK . (2009). Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. Int J Cancer 127: 239–244.

    Article  Google Scholar 

  • Davies M, Stemke-Hale K, Tellez C, Calderone T, Deng W, Prieto V et al. (2008). A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99: 1265–1268.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M et al. (2002). Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 62: 89–98.

    CAS  PubMed  Google Scholar 

  • Dummler B, Tschopp O, Hynx D, Yang Z, Dirnhofer S, Hemmings B . (2006). Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol 26: 8042–8051.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Easton R, Cho H, Roovers K, Shineman D, Mizrahi M, Forman M et al. (2005). Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25: 1869–1878.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Friday B, Adjei A . (2005). K-ras as a target for cancer therapy. Biochim Biophys Acta 1756: 127–144.

    CAS  PubMed  Google Scholar 

  • Gallegos Ruiz M, Floor K, Roepman P, Rodriguez J, Meijer G, Mooi W et al. (2008). Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 3: e0001722.

    Article  PubMed  Google Scholar 

  • Gills J, Dennis P . (2009). Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11: 102–110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gonzalez E, McGraw T . (2009). The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 8: 2502–2508.

    Article  CAS  PubMed  Google Scholar 

  • Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD et al. (2007). Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 13: 2281–2289.

    Article  CAS  PubMed  Google Scholar 

  • Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M et al. (2003). Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4: 111–120.

    Article  CAS  PubMed  Google Scholar 

  • Gupta S, Ramjaun A, Haiko P, Wang Y, Warne P, Nicke B et al. (2007). Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957–968.

    Article  CAS  PubMed  Google Scholar 

  • Hahn W, Dessain S, Brooks M, King J, Elenbaas B, Sabatini D et al. (2002). Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 22: 2111–2123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hollander M, Sheikh M, Bulavin D, Lundgren K, Augeri-Henmueller L, Shehee R et al. (1999). Genomic instability in Gadd45a-deficient mice. Nat Genet 23: 176–184.

    Article  CAS  PubMed  Google Scholar 

  • Hollander MC, Balogh AR, Liwanag J, Han W, Linnoila RI, Anver MR et al. (2008). Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/− mice. Neoplasia 10: 866–872.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jemal A, Siegel R, Xu J, Ward E . (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.

    Article  PubMed  Google Scholar 

  • Jiang HL, Xu CX, Kim YK, Arote R, Jere D, Lim HT et al. (2009). The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials 30: 5844–5852.

    Article  CAS  PubMed  Google Scholar 

  • John LC . (2001). Assessment of murine lung tumour development: a comparison of two techniques. Br J Biomed Sci 58: 159–163.

    CAS  PubMed  Google Scholar 

  • Johnson L, Mercer K, Greenbaum D, Bronson R, Crowley D, Tuveson D et al. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111–1116.

    Article  CAS  PubMed  Google Scholar 

  • Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li S et al. (2007). Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA 104: 7438–7443.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Khosravi-Far R, White M, Westwick J, Solski P, Chrzanowska-Wodnicka M, Van Aelst L et al. (1996). Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 16: 3923–3933.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lin L, Festing M, Devereux T, Crist K, Christiansen S, Wang Y et al. (1998). Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp Lung Res 24: 481–497.

    Article  CAS  PubMed  Google Scholar 

  • Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade III JL, Giguere JK et al. (2005). A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs 23: 485–487.

    Article  CAS  PubMed  Google Scholar 

  • Madhunapantula SV, Robertson GP . (2009). The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 22: 400–419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S et al. (2008). Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7: 665–669.

    Article  CAS  PubMed  Google Scholar 

  • Manning B, Cantley L . (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261–1274.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maroulakou I, Oemler W, Naber S, Tsichlis P . (2007). Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67: 167–177.

    Article  CAS  PubMed  Google Scholar 

  • Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M et al. (2009). Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69: 4885–4893.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robertson GP . (2005). Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 24: 273–285.

    Article  CAS  PubMed  Google Scholar 

  • Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y et al. (2009). The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 101: 145–148.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Skeen JE, Bhaskar PT, Chen CC, Chen WS, Peng XD, Nogueira V et al. (2006). Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10: 269–280.

    Article  CAS  PubMed  Google Scholar 

  • Steelman L, Stadelman K, Chappell W, Horn S, Basecke J, Cervello M et al. (2008). Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12: 1139–1165.

    Article  CAS  PubMed  Google Scholar 

  • Swift S, Lorens J, Achacoso P, Nolan G . (2001). Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol, Chapter 10, Unit 10.17C.

  • Trotman L, Alimonti A, Scaglioni P, Koutcher J, Cordon-Cardo C, Pandolfi P . (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523–527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tsurutani J, Fukuoka J, Tsurutani H, Shih J, Hewitt S, Travis W et al. (2006). Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24: 306–314.

    Article  CAS  PubMed  Google Scholar 

  • West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA . (2004). Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′-kinase/Akt pathway in vitro and in vivo. Cancer Res 64: 446–451.

    Article  CAS  PubMed  Google Scholar 

  • Witschi HP . (1981). Enhancement of tumor formation in mouse lung by dietary butylated hydroxytoluene. Toxicology 21: 95–104.

    Article  CAS  PubMed  Google Scholar 

  • Xu CX, Jere D, Jin H, Chang SH, Chung YS, Shin JY et al. (2008). Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am J Respir Crit Care Med 178: 60–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zilberman D, Cohen Y, Amariglio N, Fridman E, Ramon J, Rechavi G . (2009). AKT1 E17K pleckstrin homology domain mutation in urothelial carcinoma. Cancer Genet Cytogenet 191: 34–37.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This project was funded through the NIH intramural research program.

Author information

Authors and Affiliations

  1. Medical Oncology Branch, NCI, NIH, Bethesda, MD, USA

    M C Hollander, C R Maier, E A Hobbs, A R Ashmore & P A Dennis

  2. Cell and Cancer Biology Branch, NCI, NIH, Bethesda, MD, USA

    R I Linnoila

Authors
  1. M C Hollander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C R Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E A Hobbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A R Ashmore
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R I Linnoila
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P A Dennis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P A Dennis.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hollander, M., Maier, C., Hobbs, E. et al. Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene 30, 1812–1821 (2011). https://doi.org/10.1038/onc.2010.556

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.556

Keywords

This article is cited by

Search

Advanced search

Quick links